Streptococcus pneumoniae News and Research

RSS
Streptococcus pneumoniae, or Pneumococcus, is a very common bacterial infection in both industrialized and developing countries. In particular, young children and the elderly represent high-risk populations of developing pneumococcal infections. According to the WHO, the bacterium kills up to one million children under the age of five years each year worldwide. It accounts for many Bacterial Meningitis cases in adults and it is the most common cause of Bacteraemia, Pneumonia, Meningitis and Otitis media in young children.
Pfizer to supply pneumococcal conjugate vaccines for infants and children

Pfizer to supply pneumococcal conjugate vaccines for infants and children

GSK joins GAVI Alliance in the Pneumococcal disease vaccine drive

GSK joins GAVI Alliance in the Pneumococcal disease vaccine drive

New understanding of cell in immune system may guide creation of effective flu vaccines: Study

New understanding of cell in immune system may guide creation of effective flu vaccines: Study

Genocea Biosciences acquires global license for novel Streptococcus pneumoniae antigens from Children’s Hospital Boston

Genocea Biosciences acquires global license for novel Streptococcus pneumoniae antigens from Children’s Hospital Boston

Prevenar 13: Immunogenic and well tolerated in young children previously vaccinated with Prevenar

Prevenar 13: Immunogenic and well tolerated in young children previously vaccinated with Prevenar

FDA provides guidance on Restanza clinical program in treatment of CABP

FDA provides guidance on Restanza clinical program in treatment of CABP

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

Intercell AG's revenues for full year 2009 increase 10.6%

Intercell AG's revenues for full year 2009 increase 10.6%

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

FDA approves Wyeth Pharmaceuticals' Prevnar 13 pneumococcal disease vaccine

FDA approves Wyeth Pharmaceuticals' Prevnar 13 pneumococcal disease vaccine

PATH to pay FDA $480,000 to speed creation of pneumococcal vaccine for developing world

PATH to pay FDA $480,000 to speed creation of pneumococcal vaccine for developing world

FDA and PATH collaborate to advance pneumococcal vaccine development for children

FDA and PATH collaborate to advance pneumococcal vaccine development for children

Good bacteria may help counteract negative effects of antibiotics in humans

Good bacteria may help counteract negative effects of antibiotics in humans

Current research suggests flu may predispose to secondary bacterial infections

Current research suggests flu may predispose to secondary bacterial infections

Presence of Streptococcus pneumoniae could predict risk of severe disease in H1N1 pandemic influenza

Presence of Streptococcus pneumoniae could predict risk of severe disease in H1N1 pandemic influenza

Pfizer provides update on Prevnar 13

Pfizer provides update on Prevnar 13

Health Canada approves Prevnar 13 vaccine for invasive pneumococcal disease

Health Canada approves Prevnar 13 vaccine for invasive pneumococcal disease

Rib-X Pharmaceuticals and MGH enter into collaborative research agreement

Rib-X Pharmaceuticals and MGH enter into collaborative research agreement

Pfizer's Prevenar 13 granted European marketing authorization

Pfizer's Prevenar 13 granted European marketing authorization

Patients' urine may provide rapid diagnosis of pneumonia

Patients' urine may provide rapid diagnosis of pneumonia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.